UBS Group
ABVX

UBS Group’s Abivax ABVX Stock Holding History

UBS Group’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246M Sell
1,844,918
-2,702,488
-59% -$306M 0.03% 557
2026
Q1 		$506M Buy
4,547,406
+123,500
+3% +$14.6M 0.08% 268
2025
Q4 		$597M Sell
4,423,906
-37,356
-0.8% -$4.08M 0.1% 202
2025
Q3 		$379M Buy
4,461,262
+4,293,606
+2,561% +$263M 0.06% 317
2025
Q2 		$1.28M Buy
167,656
+5,102
+3% +$33.3K ﹤0.01% 5225
2025
Q1 		$1.02M Sell
162,554
-12,319
-7% -$83.4K ﹤0.01% 5277
2024
Q4 		$1.28M Buy
174,873
+174,182
+25,207% +$1.6M ﹤0.01% 5122
2024
Q3 		$7.96K Buy
+691
New +$8.28K ﹤0.01% 7863
2024
Q2 		– Sell
-3
Closed -$43 – 9461
2024
Q1 		$43 Buy
+3
New +$39 ﹤0.01% 8944

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

UBS Group's ABVX Position: Q2 2026 in Review

UBS Group reduced its Abivax (ABVX) stake by 59% in Q2 2026, selling an estimated $306M and leaving 1,844,918 shares worth $246M. The position accounts for 0.03% of the portfolio, ranked #557.

UBS Group first reported a position in ABVX in Q1 2024 and has held it in 9 quarters since. The position peaked at $597M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • UBS Group held 1,844,918 shares of Abivax worth $246M as of Q2 2026.
  • UBS Group sold 2,702,488 Abivax shares in Q2 2026, an estimated $306M.
  • Abivax made up 0.03% of UBS Group's portfolio in Q2 2026, its #557 holding.
  • UBS Group first reported a position in Abivax in Q1 2024 and has held it in 9 quarters since.
  • UBS Group's Abivax position peaked at $597M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.